SGO:无铂化疗不能提高宫颈癌患者生存率

2013-04-07 沈牡丹译医学论坛网

　　3月10日，来自加利福尼亚大学欧文医学院的Krishnansu Tewari博士在2013年SGO妇科肿瘤年会上发表了最新一项研究成果：与标准化疗法相比，无铂化疗不能提高晚期宫颈癌患者的生存率，但其有作为替代疗法的潜力。　　托泊替康-紫杉醇新二联化疗患者总生存数（OS）中位数为12.5个月，顺铂-紫杉醇二联化疗患者OS中位数为15个月，二者差异无统计学意义。卵巢癌患者行顺铂

　　3月10日，来自加利福尼亚大学欧文医学院的Krishnansu Tewari博士在2013年SGO妇科肿瘤年会上发表了最新一项研究成果：与标准化疗法相比，无铂化疗不能提高晚期宫颈癌患者的生存率，但其有作为替代疗法的潜力。

　　托泊替康-紫杉醇新二联化疗患者总生存数（OS）中位数为12.5个月，顺铂-紫杉醇二联化疗患者OS中位数为15个月，二者差异无统计学意义。卵巢癌患者行顺铂-紫杉醇二联化疗，应答率高，无进展生存期（PFS）、缓解率以及完全缓解率均提高。

　　用托泊替康代替顺铂不能提高总生存数。但是，托泊替康-紫杉醇也可作为不耐受顺铂-紫杉醇患者的一种替代疗法。当患者通过毒性筛查与评估被识别出不耐受顺铂-紫杉醇，她们可以考虑托泊替康-紫杉醇。”

　　多中心临床试验已经确定以铂为基础的化疗作为治疗宫颈癌的一线药。然而，越来越多的局部晚期宫颈癌患者使用顺铂放化疗，引发了人们对铂类耐药的复发性癌症的担忧。多项临床试验数据显示，随着接受有铂化疗的患者越来越多，与既往的一线药物疗效相比，复发性癌症的应答率越来越低。

与宫颈癌相关的拓展阅读：

LOS ANGELES -- A platinum-free regimen for advanced cervical cancer failed to improve survival compared with standard therapy, but did show potential as an alternative treatment, according to a study reported here.

The chemotherapy doublet of topotecan and paclitaxel resulted in a median overall survival (OS) of 12.5 months compared with 15 months for patients who received a cisplatin-paclitaxel doublet, but the difference did not reach statistical significance, said Krishnansu Tewari, MD, during a presentation at the Society of Gynecologic Oncology meeting.....

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2013-07-30 tamgche

#SGO#

38 0
[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2013-09-12 tastas

#患者生存#

48 0
[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2014-02-12 ms3153534357578991

#铂#

49 0
[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2013-04-09 guoyibin

#生存率#

45 0
[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2013-04-09 一闲

#宫颈#

46 0
[GetPortalCommentsPageByObjectIdResponse(id=2040140, encodeId=f1a42040140aa, content=<a href='/topic/show?id=3cb21623358' target=_blank style='color:#2F92EE;'>#SGO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16233, encryptionId=3cb21623358, topicName=SGO)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Tue Jul 30 23:37:00 CST 2013, time=2013-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932459, encodeId=37a8193245950, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Thu Sep 12 02:37:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737445, encodeId=7f7b1e374457d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Feb 12 18:37:00 CST 2014, time=2014-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256458, encodeId=148e1256458e6, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407896, encodeId=ce6d140e89654, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490064, encodeId=d266149006437, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Apr 09 04:37:00 CST 2013, time=2013-04-09, status=1, ipAttribution=)]
2013-04-09 drj2006

#铂化疗#

36 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

SGO:无铂化疗不能提高宫颈癌患者生存率

相关资讯

科室

工具

服务